Sepsis is the body’s overwhelming and life-threatening response to infection that can lead to tissue damage, organ failure and death.1 In the United States, one person is diagnosed with sepsis every 20 seconds.1 In total, 1.6 million people are diagnosed with sepsis each year.1
For in vitro diagnostics use only.
Procalcitonin (PCT) helps determine if a patient has a bacterial infection (sepsis), the severity of the infection and whether the patient is responding to therapy.2 PCT is a more accurate diagnostic parameter for sepsis, a better predictor of mortality and a more reliable marker than other biomarkers, including C-reactive protein (CRP), Interleukins and Lactate levels.3
Abbott is committed to increasing awareness about sepsis and has developed several educational resources to help clinicians and laboratorians learn more about sepsis.
For In Vitro Diagnostic Use Only
CAUTION: United States Federal law restricts this device to sale and distribution by or on the order of a physician, or to a clinical laboratory.
For complete assay information, see the assay specific package insert.
ARCHITECT B∙R∙A∙H∙M∙S PCT
Intended Use: The ARCHITECT B∙R∙A∙H∙M∙S PCT assay is a chemiluminescent microparticle immunoassay (CMIA) for the quantitative determination of procalcitonin (PCT) in human serum and plasma (lithium heparin and K2EDTA) on the ARCHITECT i System.
Used in conjunction with other laboratory findings and clinical assessments, the ARCHITECT B∙R∙A∙H∙M∙S PCT assay is intended for use as an:
Aid in the risk assessment of critically ill patients on their first day of intensive care unit (ICU) admission for progression to severe sepsis and septic shock.
Warning: The ARCHITECT B∙R∙A∙H∙M∙S PCT assay is not indicated to be used as a stand-alone diagnostic assay and should be used in conjunction with clinical signs and symptoms of infection and other diagnostic evidence.
Decisions regarding antibiotic therapy should NOT be based solely on PCT concentrations. PCT results should always be interpreted in the context of the clinical status of the patient and other laboratory results. Changes in PCT levels for the prediction of mortality, and overall mortality, are strongly dependent on many factors, including pre-existing patient risk factors and clinical course. The need to continue ICU care at Day 4 and other covariates (e.g., age and SOFA score) are also significant predictors of 28-day cumulative mortality risk. Certain patient characteristics, such as severity of renal failure or insufficiency, may influence PCT values and should be considered as potentially confounding clinical factors when interpreting PCT values. PCT levels may not be elevated in patients infected by certain atypical pathogens, such as Chlamydophila pneumoniae and Mycoplasma pneumoniae.
Low PCT levels do not always indicate absence of bacterial infection. Falsely low PCT levels in the presence of bacterial infection may occur during the early course of infections, in localized infections, and in subacute infectious endocarditis.
Increased PCT levels may not always be related to systemic bacterial infection. The safety and performance of PCT-guided therapy for individuals younger than age 18 years, pregnant women, immunocompromised individuals or those on immunomodulatory agents, was not formally analyzed in the supportive clinical trials. ARCHITECT B∙R∙A∙H∙M∙S PCT results should not be used interchangeably with other methods for PCT determinations for monitoring patients.
|
|
Links which take you out of Abbott worldwide websites are not under the control of Abbott, and Abbott is not responsible for the contents of any such site or any further links from such site. Abbott is providing these links to you only as a convenience, and the inclusion of any link does not imply endorsement of the linked site by Abbott. The website that you have requested also may not be optimised for your screen size.
Please be aware that the website you have requested is intended for the residents of a particular country or countries, as noted on that site. As a result, the site may contain information on pharmaceuticals, medical devices and other products or uses of those products that are not approved in other countries or regions.
